Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients

Seminars in Dialysis

Volumn 20, Issue 6, 2007, Pages 523-529

  Suliman, Mohamed E ^a   Lindholm, Bengt ^a   Bárány, Peter ^a   Qureshi, Abdul Rashid ^a   Stenvinkel, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; VITAMIN;

BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; GENETICS; HUMAN; HYPERHOMOCYSTEINEMIA; PROGNOSIS; REVIEW;

CARDIOVASCULAR DISEASES; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; PROGNOSIS; VITAMINS;

EID: 35948971836     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2007.00336.x     Document Type: Review

References (80)

1. McCully KS, Wilson RB : Homocysteine theory of arteriosclerosis. Atherosclerosis 22 : 215 227, 1975
2. McCully KS : Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56 : 111 128, 1969
3. Kaul S, Zadeh AA, Shah PK : Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated. J Am Coll Cardiol 48 : 914 923, 2006
4. Cook JW, Taylor LM, Orloff SL, Landry GJ, Moneta GL, Porter JM : Homocysteine and arterial disease. Experimental mechanisms. Vascul Pharmacol 38 : 293 300, 2002
5. Danesh J, Lewington S : Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 5 : 229 232, 1998
6. Homocysteine Studies Collaboration : Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288 : 2015 2022, 2002
7. Wald DS, Law M, Morris JK : Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325 : 1202, 2002
8. Brattström L, Wilcken DE : Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 72 : 315 323, 2000
9. Toole JF, Malinow MR, Chambless LE, et al. : Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291 : 565 575, 2004
10. Bonaa KH, Njolstad I, Ueland PM, et al. : Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354 : 1578 1588, 2006
11. Lonn E, Yusuf S, Arnold MJ, et al. : Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354 : 1567 1577, 2006
12. Suliman ME, Barany P, Kalantar-Zadeh K, et al. : Homocysteine in uraemia - a puzzling and conflicting story. Nephrol Dial Transplant 20 : 16 21, 2005
13. Chauveau P, Chadefaux B, Coude M, et al. : Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl 41 : S72 77, 1993
14. Bachmann J, Tepel M, Raidt H, et al. : Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 6 : 121 125, 1995
15. Robinson K, Gupta A, Dennis V, et al. : Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94 : 2743 2748, 1996
16. Jungers P, Chauveau P, Bandin O, et al. : Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients. Miner Electrolyte Metab 23 : 170 173, 1997
17. Manns BJ, Burgess ED, Hyndman ME, et al. : Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis 34 : 669 677, 1999
18. Kunz K, Petitjean P, Lisri M, et al. : Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link? Nephrol Dial Transplant 14 : 1934 1942, 1999
19. Suliman ME, Qureshi AR, Bárány P, et al. : Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 57 : 1727 1735, 2000
20. Suliman ME, Stenvinkel P, Heimbürger O, et al. : Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. Am J Kidney Dis 40 : 480 488, 2002
21. Sirrs S, Duncan L, Djurdjev O, et al. : Homocyst(e)ine and vascular access complications in haemodialysis patients: insights into a complex metabolic relationship. Nephrol Dial Transplant 14 : 738 743, 1999
22. Wrone EM, Zehnder JL, Hornberger JM, et al. : An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int 60 : 1106 1113, 2001
23. Vychytil A, Fodinger M, Wolfl G, et al. : Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. Kidney Int 53 : 1775 1782, 1998
24. Bostom AG, Shemin D, Verhoef P, et al. : Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 17 : 2554 2558, 1997
25. Moustapha A, Naso A, Nahlawi M, et al. : Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97 : 138 141, 1998
26. Mallamaci F, Zoccali C, Tripepi G, et al. : Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 61 : 609 614, 2002
27. Dierkes J, Domrose U, Westphal S, et al. : Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 102 : 1964 1969, 2000
28. Ducloux D, Bresson-Vautrin C, Kribs M, et al. : C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 62 : 1417 1422, 2002
29. Kronenberg F, Mundle M, Langle M, et al. : Prevalence and progression of peripheral arterial calcifications in patients with ESRD. Am J Kidney Dis 41 : 140 148, 2003
30. Kalantar-Zadeh K, Block G, Humphreys MH, et al. : A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 15 : 442 453, 2004
31. Wrone EM, Hornberger JM, Zehnder JL, et al. : Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 15 : 420 426, 2004
32. Bayes B, Pastor MC, Bonal J, et al. : Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 18 : 106 112, 2003
33. London GM, Pannier B, Agharazii M, et al. : Forearm reactive hyperemia and mortality in end-stage renal disease. Kidney Int 65 : 700 704, 2004
34. Suliman ME, Stenvinkel P, Barany P, et al. : Hyperhomocysteinemia, malnutrition, and inflammation in ESRD patients. Semin Nephrol 26 : 14 19, 2006
35. Menon V, Sarnak MJ, Greene T, et al. : Relationship between homocysteine and mortality in chronic kidney disease. Circulation 113 : 1572 1577, 2006
36. Shastry S, Ingram AJ, Scholey JW, et al. : Homocysteine induces mesangial cell apoptosis via activation of p38-mitogen-activated protein kinase. Kidney Int 71 : 304 311, 2007
37. Jager A, Kostense PJ, Nijpels G, et al. : Serum homocysteine levels are associated with the development of (micro)albuminuria: the Hoorn study. Arterioscler Thromb Vasc Biol 21 : 74 81, 2001
38. Ninomiya T, Kiyohara Y, Kubo M, et al. : Hyperhomocysteinemia and the development of chronic kidney disease in a general population: the Hisayama study. Am J Kidney Dis 44 : 437 445, 2004
39. Anderson JL, King GJ, Thomson MJ, et al. : A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol 30 : 1206 1211, 1997
40. Lewis SJ, Ebrahim S, Davey Smith G : Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ 331 : 1053, 2005
41. Aucella F, Margaglione M, Grandone E, et al. : The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: results of a multicentre prospective study. Nephrol Dial Transplant 20 : 382 386, 2005
42. Liao D, Tan H, Hui R, et al. : Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance. Circ Res 99 : 598 606, 2006
43. Mikael LG, Genest J Jr., Rozen R : Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res 98 : 564 571, 2006
44. El-Khairy L, Ueland PM, Refsum H, et al. : Plasma total cysteine as a risk factor for vascular disease: The European Concerted Action Project. Circulation 103 : 2544 2549, 2001
45. Kerins DM, Koury MJ, Capdevila A, et al. : Plasma S-adenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine. Am J Clin Nutr 74 : 723 729, 2001
46. Riksen NP, Rongen GA, Blom HJ, et al. : Potential role for adenosine in the pathogenesis of the vascular complications of hyperhomocysteinemia. Cardiovasc Res 59 : 271 276, 2003
47. Nygård O, Vollset SE, Refsum H, et al. : Total homocysteine and cardiovascular disease. J Intern Med 246 : 425 454, 1999
48. Dong C, Yoon W, Goldschmidt-Clermont PJ : DNA methylation and atherosclerosis. J Nutr 132 : 2406S 2409S, 2002
49. Ingrosso D, Cimmino A, Perna AF, et al. : Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 361 : 1693 1699, 2003
50. Stenvinkel P, Karimi M, Johansson S, et al. : DNA hypermethylation is an independent predictor of all-cause and cardiovascular mortality and related to inflammation in chronic kidney disease. J Intern Med 261 : 488 499, 2007
51. Kalantar-Zadeh K, Fouque D, Kopple JD : Outcome research, nutrition, and reverse epidemiology in maintenance dialysis patients. J Ren Nutr 14 : 64 71, 2004
52. Stenvinkel P, Heimbürger O, Lindholm B, et al. : Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome) Nephrol Dial Transplant 15 : 953 960, 2000
53. Kalantar-Zadeh K, Ikizler TA, Block G, et al. : Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 42 : 864 881, 2003
54. Oishi K, Nagake Y, Yamasaki H, et al. : The significance of serum homocysteine levels in diabetic patients on haemodialysis. Nephrol Dial Transplant 15 : 851 855, 2000
55. Suliman ME, Stenvinkel P, Qureshi AR, et al. : Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. Am J Kidney Dis 44 : 455 465, 2004
56. Stenvinkel P, Heimbürger O, Paultre F, et al. : Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55 : 1899 1911, 1999
57. Qureshi AR, Alvestrand A, Divino-Filho JC, et al. : Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 13 (Suppl. 1 S28 S36, 2002
58. Ducloux D, Klein A, Kazory A, et al. : Impact of malnutrition- inflammation on the association between homocysteine and mortality. Kidney Int 69 : 331 335, 2006
59. Suliman M, Stenvinkel P, Qureshi AR, et al. : The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol Dial Transplant 22 : 209 217, 2007
60. Kalantar-Zadeh K, Block G, Humphreys MH, et al. : Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63 : 793 808, 2003
61. Boushey CJ, Beresford SA, Omenn GS, et al. : A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274 : 1049 1057, 1995
62. Zoccali C, Testa A, Spoto B, et al. : Mendelian randomization: a new approach to studying epidemiology in ESRD. Am J Kidney Dis 47 : 332 341, 2006
63. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 151 : 282 287, 2006
64. Zoungas S, McGrath BP, Branley P, et al. : Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 47 : 1108 1116, 2006
65. Loscalzo J : Homocysteine trials - clear outcomes for complex reasons. N Engl J Med 354 : 1629 1632, 2006
66. Scholze A, Rinder C, Beige J, et al. : Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 109 : 369 374, 2004
67. Urquhart BL, Freeman DJ, Spence JD, et al. : The effect of mesna on plasma total homocysteine concentration in hemodialysis patients. Am J Kidney Dis 49 : 109 117, 2007
68. Zoccali C, Mallamaci F : Homocysteine and risk in end-stage renal disease: a matter of context. Kidney Int 69 : 204 206, 2006
69. Buccianti G, Baragetti I, Bamonti F, Furiani S, Dorighet V, Patrosso C : Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol 17 : 405 410, 2004
70. Mallamaci F, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Candela V, Scudo P, Spoto B, Testa A, Tripepi G, Tech S, Zoccali C : Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients. Am J Kidney Dis 45 : 702 707, 2005
71. Tsai JC, Kuo HT, Chiu YW, Hwang SJ, Chuang HY, Chang JM, Chen HC, Lai YH : Correlation of plasma homocysteine level with arterial stiffness and pulse pressure in hemodialysis patients. Atherosclerosis 182 : 121 127, 2005
72. Anan F, Takahashi N, Shimomura T, Imagawa M, Yufu K, Nawata T, Nakagawa M, Yonemochi H, Eshima N, Saikawa T, Yoshimatsu H : Hyperhomocysteinemia is a significant risk factor for silent cerebral infarction in patients with chronic renal failure undergoing hemodialysis. Metabolism 55 : 656 661, 2006
73. Busch M, Franke S, Muller A, Wolf M, Gerth J, Ott U, Niwa T, Stein G : Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 66 : 338 347, 2004
74. Leskinen Y, Lehtimaki T, Loimaala A, Huhtala H, Salenius JP, Oja SS, Saha H : Homocysteine and carotid atherosclerosis in chronic renal failure - the confounding effect of renal function. Atherosclerosis 175 : 315 323, 2004
75. Friedman AN, Hunsicker LG, Selhub J, Bostom AG : Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy. J Am Soc Nephrol 16 : 3397 3402, 2005
76. Wang AY, Lam CW, Wang M, Woo J, Chan IH, Lui SF, Sanderson JE, Li PK : Circulating soluble vascular cell adhesion molecule 1: relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients. Am J Kidney Dis 45 : 715 729, 2005
77. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C : Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 16 : 2449 2455, 2005
78. Nair AP, Nemirovsky D, Kim M, Geer EB, Farkouh ME, Winston J, Halperin JL, Robbins MJ : Elevated homocysteine levels in patients with end-stage renal disease. Mt Sinai J Med 72 : 365 373, 2005
79. Suliman ME, Stenvinkel P, Jogestrand T, Maruyama Y, Qureshi AR, Barany P, Heimburger O, Lindholm B : Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. Clin Nephrol 66 : 418 425, 2006
80. Kumagai H, Sakurai M, Takita T, Maruyama Y, Uno S, Ikegaya N, Kato A, Hishida A : Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. Am J Kidney Dis 48 : 797 805, 2006